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Albendazole is a first line drug for the treatment of several parasitic diseases in humans. 26 
Some parasites target the lungs, however lung delivery of albendazole has so far not been 27 
reported. We have developed albendazole-based powders suitable for pulmonary 28 
delivery, and studied the impact of surfactant on the formulation properties. High- 29 
pressure homogenization followed by spray drying was used to produce inhalable 30 
particles of albendazole containing the bile salts sodium taurocholate and sodium 31 
glycocholate. The process resulted in porous microparticles, that exhibited good spray 32 
drying yield (> 50%), low moisture contents (< 1%) and aerodynamic D90 < 5 µm. The 33 
particles showed adequate aerosolization performance either for normal conditions 34 
(respiratory fraction > 71%) or conditions that simulate decreased respiratory capacity 35 
(respiratory fraction > 49%). The powders did not dis urb lung surfactant function. The 36 
comparison between both formulations has revealed that the properties of the surfactants 37 
affect mainly the particle size of the suspensions and the porosity of the powders. The 38 
higher porosity of the albendazole-sodium taurocholate powder led to an enhanced 39 
aerodynamic performance of the formulation compared to albendazole-sodium 40 
glycocholate. The developed albendazole powders may pave a way for local lung 41 
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1. Introduction 53 
Hydatidosis or human cystic echinococcosis (CE) is a cosmopolitan zoonotic disease that 54 
can be found in people and livestock infected with the larval stage of the nematode 55 
Echinococcus granulosus [1]. In humans, the outcome of this infection is cyt 56 
development in different organ systems, with the liv r (65%) and the lungs (25%) being 57 
the most commonly affected organs [2, 3]. Since lungs have high elasticity, pulmonary 58 
cysts grow very fast [4].  59 
Albendazole (ABZ) is the drug of choice for chemotherapeutic treatment of CE [5, 6]. It 60 
is known that the success of the chemotherapeutic treatment of CE depends on the 61 
capacity of the drug to access to the hydatid cyst at adequate concentrations for sufficient 62 
periods of time [7]. Since drugs administered by the oral route, once absorbed, access to 63 
the liver through the portal vein to be metabolized, this route is useful for treatment of 64 
hepatic hydatid cysts. Treatment of pulmonary CE by local administration of ABZ 65 
through the pulmonary route has so far been an unexplored alternative. There are several 66 
advantages of delivering drugs directly to the lungs, it allows the use of lower doses than 67 
those required orally, while it reduces possible side effects and, at the same time, high 68 
local concentrations are reached at the site of action [8]. 69 
Designing suitable aerosols for inhalation is challenging. Particle size is one of the most 70 
important characteristics in dry powder inhaler formulations, together with shape, 71 
porosity, density, electrical charge and hygroscopiity [9]. In order to reach the lower 72 
respiratory tract and optimize pulmonary drug deposition, the formulations need to have 73 
aerodynamic diameters between 0.5 and 5 µm [10]. Once in the respiratory parts of the 74 
lungs, particles can interact with components of the lung surfactant (LS) film and this 75 
interaction depends on the physical properties of the particles [11]. 76 
A widely used method to produce particles for pulmonary delivery is spray drying (SD) 77 
[9]. One of the main advantages of this technique is that the characteristics of the 78 
resulting particles can be controlled by adjusting he formulation and process parameters 79 















solubility of drugs is very low preparation of solutions using organic solvents or aqueous 81 
suspensions are some of the available alternatives. The main disadvantage of organic 82 
solvents is their toxicity related to the presence of residual solvents in the final product, 83 
therefore, aqueous suspensions are preferred [9].  84 
Since suspensions are unstable heterogeneous mixtures, hey must be stabilized. One 85 
way to stabilize suspensions is by using surfactants. I  the literature on pulmonary 86 
delivery, bile salts, such as salts of cholate, deoxycholate, glycocholate, 87 
glycodeoxycholate, taurocholate and taurodeoxycholate are used [14-21]. Bile salts have 88 
other important roles in drug absorption and the aerodynamic properties of powders [14]. 89 
Therefore, the selection of the surfactant is a relevant formulation factor.   90 
During the spray drying process, solid drugs in suspen ion aggregate and form dried 91 
particles with a larger size than the starting materi l [9]. Hence, in order to obtain 92 
microparticles suitable for pulmonary deposition by SD, suspensions need to be 93 
previously processed to obtain particles in the nanometric range (e.g. by high-pressure 94 
homogenization, HPH).  95 
As mentioned above, to date, no formulations targetin  ABZ to the lung have been 96 
reported. Therefore, the present study has addressed the production, characterization and 97 
comparison of new dry powder formulations based on albendazole and two different bile 98 
salts, namely sodium taurocholate (STC) and sodium glycocholate (SGC), for pulmonary 99 
delivery. The novel formulations were obtained by processing ABZ-bile salts 100 
suspensions by high-pressure homogenization followed by spray drying. Both 101 
formulations were characterized and compared in terms of particle size, surface tension, 102 
morphology, powder density, porosity and aerodynamic properties. The effect of the 103 
ABZ-bile salt formulations on LS function was also evaluated.  104 
The ABZ-bile salt formulations manufactured and characterized in the present article 105 
have the potential for filling the therapeutic niche of treating pulmonary parasitic 106 
















2. Materials and methods 109 
2.1. Materials 110 
ABZ and lactose monohydrate (both pharmaceutical grade), as well as gelatin capsules 111 
number 3 were purchased from Saporiti (Buenos Aires, Argentina). Sieved lactose (+100 112 
ASTM mesh) with D10= 167.8 µm, D50= 234.9 µm and D90= 336.4 µm was used as a 113 
carrier. STC and SGC (both analytical grade), were purchased from Sigma Aldrich (St. 114 
Luis, MO, USA). Curosurf was produced by Chiesi (Parm , Italy). The unidose RS01 115 
high resistance inhaler (Plastiape, Milano, Italy) nd the multidose Turbuhaler device 116 
(AstraZeneca, Gothenburg, Sweden) were used as model inhalers. Ethyl alcohol 96% 117 
(Pharmacopoeia quality, Porta, Argentina) and bidistilled water were also used.  118 
 119 
2.2. Characterization of the ABZ-bile salt suspensions  120 
2.2.1. Preparation and particle size analysis of suspensions 121 
Aqueous solutions containing either STC or SGC (0.03% w/v) were prepared. ABZ 122 
suspensions were obtained by adding ABZ (1% w/v) to the surfactant solution under 123 
magnetic stirring for 30 min. The bile salt concentration in the suspension was selected 124 
based on stability [22] and safety considerations [17, 21] (for more details, please see 125 
Section 1.S in the Supplementary material).  126 
After dispersion, the suspensions were subjected to a first size reduction step using a 127 
PRO200 homogenizer (Tecnolab, Argentina) at 30,000 rpm (10 min for a sample of 500 128 
mL). Then, a second reduction/deagglomeration step using sonication (Cole Parmer 129 
ultrasonic cleaner) (10 min for a sample of 500 mL,at a frequency of 40 kHz) was 130 
performed. Samples were withdrawn after each step to valuate particle size 131 
distributions. 132 
The particle size distributions were determined by using laser diffraction (LA 950V2, 133 
Horiba, Kyoto, Japan, Liquid method). For the measurement, 2 mL of suspensions were 134 















The average size distribution was reported as median volumetric diameter (D50) and the 136 
distribution width was informed as span (see Eq.1). 137 
 138 




		                                                   (1) 139 
 140 
In Eq. 1, D10, D50 and D90 represent the diameters where the 10%, 50% and 90% of the 141 
population is below each value, respectively. Span values below 2 indicate relatively 142 
narrow distributions [23]. 143 
 144 
2.2.2. Surface tension determination 145 
In order to analyze the effect of the type of bile salt over the surface tension of the 146 
suspensions, the surface tension of bidistilled water, STC solution (0.03% w/v), SGC 147 
solution (0.03% w/v), ABZ-STC suspension after homogenization/sonication and ABZ-148 
SGC suspension after homogenization/sonication was determined.  149 
The measurements were performed with a ring Krüss ten iometer (Krüss GmbH, 150 
Hamburg, Germany). All determinations were carried out in duplicate at a temperature of 151 
20.7 ± 0.4 °C. 152 
 153 
2.3. Preparation and particle size analysis of nanosuspensions 154 
The suspensions were further processed by HPH technique (APV homogenizer, Soeborg, 155 
Denmark) to obtain nanosuspensions. The coarse suspnsions (Section 2.2.1) were 156 
subjected to HPH for 10, 20 and 30 cycles at 800 bar. By using an external heat 157 
exchanger, the suspension temperature was maintained t around 30°C. The intensity-158 
weighted average hydrodynamic diameter and polydispersity index (PdI) of the aqueous 159 
nanosuspensions were determined by photon correlation spectroscopy (PCS) using a 160 
Zetasizer Nano ZS (Malvern Instruments, UK). For this measurement, the 161 















0.25% w/v. Mean particle diameters were reported as “Z-aver ge” diameters. All 163 
determinations were carried out in triplicate. 164 
 165 
2.4. Spray drying 166 
The aqueous nanosuspensions were atomized in a lab-scale spray drier (Mini Spray 167 
Dryer B-290, BÜCHI, Flawil, Switzerland) equipped with a high performance cyclone. 168 
A two-fluid nozzle with a cap-orifice diameter of 0.5 mm was used. The nanosuspensions 169 
were spray dried under constant stirring to keep th samples homogeneous. The 170 
following conditions were used during the procedure: air inlet temperature (co-current 171 
flow): 110°C; drying air flowrate: 35 m3/h; liquid feed flowrate: 1.5 mL/min and 172 
atomization air flowrate: 670 L/h. These conditions were selected based on preliminary 173 
studies. The process yield was calculated as the raio of the powder weight obtained in 174 
the product collection vessel with respect to the total solids fed to the system. All 175 
determinations were carried out in duplicate. 176 
 177 
2.5. Characterization of the SD products 178 
2.5.1. Moisture content 179 
The moisture content of the SD products was measured using a halogen moisture 180 
analyzer (MB45, Ohaus, Pine Brook, United States). The determination was carried out 181 
using samples of around 500 mg. They were heated up to 80°C until the weight changes 182 
were less than 1 mg in 60 s.  183 
 184 
2.5.2. Particle size analysis 185 
The particle size distribution (PSD) of powders obtained by spray drying (SD ABZ-STC 186 
and SD ABZ-SGC) was obtained by laser diffraction (LA 950V2, Horiba, Kyoto, Japan), 187 
using the dry powder method. Since the resulting powders were cohesive, the SD 188 
samples were dispersed in relative coarse lactose (sample:lactose =1:4) to improve the 189 















with the PSD of the microparticles obtained by spray drying. The PSDs for ABZ and 191 
lactose were also measured in triplicate. 192 
 193 
2.5.3. Scanning electron microscopy (SEM) 194 
The morphology of ABZ raw material and the SD powders ABZ-STC and ABZ-SGC 195 
was analyzed by scanning electron microscopy (SEM), using a EVO 40-XVP, LEO 196 
scanning electron microscope (Oberchoken, Germany). The samples were metalized with 197 
a thin layer of gold using a sputter coater (PELCO 91000, TellPella, Canada). The 198 
scanning electron microscope was operated at an acceleration voltage of 10 kV. 199 
 200 
2.5.4. Bulk and tap density 201 
Bulk and tap density of ABZ raw material, SD powders (ABZ-STC and ABZ-SGC) and 202 
lactose were measured by using a 10 mL graduated cylinder. Bulk density (δbulk) was 203 
calculated as the ratio of the weight of the powder poured in the cylinder with respect to 204 
the volume occupied by the powder. Tap density (δtap) was calculated by tapping the 205 
cylinder until no measurable change in volume was observed. All determinations were 206 
made in triplicate. Carr Index (CI) was calculated using Eq.(2) and the results were 207 
interpreted according USP classification [25]. 208 
 209 
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2.5.5. Porosity 212 
Pore size distribution of the SD ABZ-STC and SD ABZ-SGC powders was determined 213 
in a Autosorb iQ gas sorption analyzer (Quantachrome Instruments, Boynton Beach, FL, 214 
USA) by using the Brunauer-Emmet-Teller (BET) method (relative pressure range: 0.05-215 
0.30).   Samples were degassed at 50°C for 24 h before analysis. Pore volume 216 
















2.5.6. Aerodynamic performance 219 
The aerodynamic particle size distribution of SD ABZ-STC and SD ABZ-SGC powders 220 
was determined using a Next Generation Impactor (NGI, Coplay, Nottingham, UK) [26, 221 
27] equipped with a pre-separator (PS).  222 
To ensure an adequate dispersibility of the particles, the samples were mixed with lactose 223 
in a ratio 1:2 (SD powder:lactose w/w) and 1:1 (SD powder:lactose w/w). It is known 224 
that during inhalation, the drug particles are detached from the surface of lactose, the 225 
carrier particles impact in the oropharynx and the upper airways and they are swallowed, 226 
while the inhalable drug particles go to the lower pa ts of the respiratory tract [28].   227 
A 3-size gelatin capsule was filled with 80 mg of the powder. The doses used represent 228 
3.25% or 5% of the maximum dose administered orally in adults (400 mg twice per day). 229 
The filled capsule was placed in a RS01 high resistance inhaler (Plastiape). The NGI 230 
stages were precoated with glycerin to avoid particle re-entrainment.  231 
Pressure drops of 2 and 4 kPa across the NGI were assayed, being the circulating air 232 
flowrate 42.5 and 60 L/min, respectively. Although USP specifies as a standard test 233 
condition a pressure drop of 4 kPa, the formulations have also been tested at 2 kPa to 234 
evaluate the effect of the inspiration rate on the aerosolization performance [26]. For 235 
both flowrates analyzed, the aerodynamic cutoff diameters of each stage of the NGI were 236 
calculated as previously described [25-27, 29].  237 
The powders deposited on the NGI stages, inhaler, induction port, mouthpiece adapter 238 
and PS were recovered with an appropriate volume of ethanol. The ABZ content in each 239 
stage or NGI component was determined by UV spectrophotometry at 217 nm. 240 
Experiments were done in triplicate. The emitted fraction (EF), the fine particle fraction 241 
(FPF) and respirable fraction (RF) were calculated s follows [30]:  242 
 243 
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 250 
The mass median aerodynamic diameter (MMAD, D50), D10 and D90 as well as the 251 
percentage of particles with aerodynamic diameters b low 5 µm, 3 µm and 1 µm were 252 
determined by using polynomial equations that adjusted for the passing volume 253 
cumulative distribution (built considering the drug mass collected in NGI-1–7 stages and 254 
the micro-orifice collector).  255 
The geometric standard deviation (GSD), which represents the spread of an aerodynamic 256 
particle size distribution, was calculated as (D84/D16)
1/2, where D84 and D16 represent the 257 
diameters at which 84% and 16% of the drug mass are recovered from the NGI 1–7 258 
stages and micro-orifice collector, respectively.  259 
 260 
2.5.7. Constrained drop surfactometer analysis 261 
The effects of ABZ-STC and ABZ-SGC powders on the LS function were analyzed by 262 
the constrained drop surfactometer (CDS) method (BioSurface Instruments, Honolulu, 263 
HI) under the operating conditions previously described by Sørli et al [31-33]. Curosurf 264 
(porcine lung surfactant, LS) was diluted in water to achieve a final concentration of 2.5 265 
mg/mL. For exposure experiments, a drop (10 µL) of the curosurf solution was placed on 266 
a pedestal. The drop was compressed/expanded less than 30% of its initial area, at a 267 
cycling frequency of 40 cycles/min to simulate the movements of the lung during 268 
breathing. For each experiment, a baseline (for the unexposed LS drop) was determined. 269 
The powders were continuously introduced into the camber by a Venturi tube connected 270 















quartz crystal microbalance (Vitrocell, Waldkirch, Germany) in real time. The dose was 272 
increased from 0 to approximately 11 µg of ABZ-STC and ABZ-SGC powders per mg of 273 
LS. The minimal surface tensions of the drop before and during exposure were analyzed 274 
for the whole range of doses using ADSA (Axisymmetric Drop Shape Analysis) [33]. 275 
The experiments were performed five times (N=5). 276 
 277 
2.6. Statistical analysis 278 
Statistical analysis was performed using multiple t-t s s, using GraphPad Prism software 279 
v6.05 (GraphPad Software Inc, San Diego, Ca, USA). p-values lower than 0.05 were 280 
considered statistically significant. Data represent the mean value ± standard deviation. 281 
The number of repetitions of the experiments is indicated in each section of Material and 282 
methods. 283 
 284 
3. Results and discussion 285 
3.1. Characterization of the suspensions of ABZ with bile salts 286 
Table 1 shows information about the particle size distributions of the raw ABZ powder 287 
and the suspensions before and after the homogenizatio  and sonication processes. ABZ, 288 
as supplied, presented a median size of 76.31 µm. By producing a suspension of ABZ 289 
with bile salts, an important decrease in the D50 value of ABZ could be observed. 290 
Interestingly, the D50 of the initial ABZ-STC suspension was about 3 times larger than 291 
the D50 exhibited by the initial ABZ-SGC suspension, suggesting that SGC is more 292 
effective as surfactant than STC. A similar behavior was found for suspensions of 293 
tobramycin with STC and SGC [34].  294 
To reduce particle size, homogenization and sonication of the dispersions were 295 
performed prior to HPH (Table 1). The homogenization process produced a 52% 296 
reduction in the D50 of the ABZ-STC system, while it did not change the D50 of ABZ-297 
SGC suspension. On the other hand, sonication significantly reduced (around 50%) the 298 















and ABZ-SGC systems, respectively. The span values, w re close to or higher than 2, 300 
indicating that all the particle size distributions were dispersed before HPH process.  301 
In order to confirm the higher capacity of SGC as surfactant, the surface tensions (ST) of 302 
water, the solutions of STC and SGC in water, and the ABZ-STC and ABZ-SGC 303 
suspensions were measured. The initial surface tension of water was 73.3 mN/m. By 304 
adding SGC, the surface tension of the solution decreased to 54.0 mN/m, whereas the 305 
addition of STC reduced the water surface tension to 63.4 mN/m. These results 306 
confirmed that SGC is more efficient at reducing the surface tension of water than STC. 307 
When the surface tension of the solutions of STC and SGC in water and the suspensions 308 
of ABZ containing SGC or STC were compared, an increase in the surface tension was 309 
observed for the ABZ-SGC suspension (64.4 mN/m), while t e value remained almost 310 
unchanged for the ABZ-STC suspension (67.9 mN/m). These results suggest that the 311 
SGC is interacting strongly with the ABZ particles in suspension [35], which explains 312 
the increase in the water surface tension, while the interaction of STC with the ABZ 313 
particles is low, leading to a similar water surface tension in the ABZ suspension.  314 
It is well known that the amidation of the carboxyl group with amino acids, such as 315 
glycine or taurine, contributes to changes in hydrophilic-lipophilic balance (HLB) of bile 316 
salts. Thus, tauroderivatives are more hydrophilic than glycoderivatives, which are more 317 
hydrophilic than the original salts [36]. Housaindokht et al.[37] synthesized 318 
nanostructured inorganic particles with various surfactants, having different HLB values 319 
and they found that particle size and PSD increased with increasing surfactant HLB 320 
values. These results are in agreement with our data, which showed that the suspension 321 
containing SGC has a significantly lower particle size than the suspension stabilized with 322 
STC (with higher HLB) during the whole process.  323 
 324 
3.2. Influence of the HPH processing on the particle size of the nanosupensions 325 
After homogenization and sonication, the suspensions of ABZ-SGC and ABZ-STC were 326 















applied homogenization cycles (Section 2S and Table S1, Supplementary material). After 328 
10 homogenization cycles (considered appropriate to produce the ABZ 329 
nanosuspensions), the Z-average diameters were 454 and 90 nm for ABZ-SGC and 330 
ABZ-STC, respectively. Results from other authors showed that after HPH process, SGC 331 
was more suitable to stabilize tobramycin nanosuspensions, compared with STC, leading 332 
to nanosuspensions of lower particle size [34]. In the case of our formulations, although 333 
the particle size of the ABZ-SGC nanosuspensions teded to be smaller compared to 334 
ABZ-STC in all the homogenization cycles performed, the differences were not 335 
statistically significant.  336 
 337 
3.3. Spray-drying process yield and outlet air temperature 338 
The nanosuspensions were then processed by spray drying. Table 2 shows the SD yield 339 
and outlet air temperature for both systems. The outl t air temperature was 340 
approximately 70 °C, well below the degradation temp rature reported for ABZ (140 °C) 341 
[38]. FT-Infrared Spectroscopy results confirmed that processing did not affect the 342 
chemical stability of the drug (Section 3.S, Supplementary material). The process yield 343 
was 50% for SD ABZ-STC and 60% for SD ABZ-SGC. The statistical analysis has 344 
shown that the differences in the yields of the formulations are not significant and that 345 
they can be considered acceptable for lab-scale driers [39]. 346 
 347 
3.4. Characterization of the SD powders  348 
3.4.1. Particle size distribution and powder moisture 349 
Table 2 presents the moisture content, D10 D50, D90 and span of the SD ABZ-STC and 350 
SD ABZ-SGC powders. Considering that a moisture content of 5% w/w is acceptable for 351 
inhalation powders [40], the combination of the selected operating conditions and 352 
formulations allowed the production of particles with very low water contents (< 1%). 353 
The comparison between formulations shows that the moisture content of SD ABZ-SGC 354 















in the ST decreases the moisture content of the dried particles due to the greater 356 
permeation of heat into the atomized liquid feed [8]. Our results (Section 3.1) showed 357 
that solutions and suspensions developed with SGC have lower surface tension than 358 
solutions and suspensions of STC. Thus, the lower moisture content of SD ABZ-SGC 359 
formulations compared with SD ABZ-STC can be due to the higher capacity of SGC to 360 
reduce the ST of ABZ formulations. 361 
The SD ABZ-SGC and ABZ-STC powders also presented suitable geometric median 362 
diameters (lower than 4 µm) for pulmonary administration. The differences in the D50 363 
values of the SD ABZ-SGC and SD ABZ-STC powders were not statistically significant. 364 
According to the span values, the SD ABZ-STC particle size distribution could be 365 
considered narrow, while it was slightly more disper e for the SD ABZ-SGC. 366 
 367 
3.4.2. Morphology  368 
The morphology of the ABZ raw material and SD powders (ABZ-STC and ABZ-SGC) 369 
was analyzed by scanning electron microscopy (SEM) (Figure 1).  370 
As shown in Figure 1A, the ABZ raw material exhibited a laminar structure [60]. The 371 
ABZ raw material presented some particles that were much larger than those observed 372 
for the SD powders. This is in agreement with data obt ined by laser diffraction for the 373 
ABZ raw material (D50 = 76.31 µm, Table 1). On the other hand, the SEM micrographs 374 
of the SD ABZ-STC and SD ABZ-SGC powders (Fig. 1B and 1C, respectively) suggest 375 
that the particles were agglomerates of small particles with a final size of approximately 376 
4 µm, also in agreement with the previous laser diffraction results of the SD ABZ-STC 377 
and SD ABZ-SGC powders (D50 = 3.72 µm and 3.86 µm, respectively, Table 2). In 378 
addition, the SD ABZ-STC and SD ABZ-SGC particles semed to present pores, due to 379 
the agglomeration of the nanoparticles. 380 
 381 















A common indicator of powder flowability is the Carr's compressibility index (CI). The 383 
flow of ABZ raw material, SD ABZ-STC, SD ABZ-SGC and lactose was evaluated by 384 
means of the CI. According to USP, CI values higher than 30 indicate poor powder 385 
flowability and values lower than 25 indicate good flow characteristics [25]. As shown 386 
in Table 3, the CI of ABZ raw material was about 35%, exhibiting poor fl w properties 387 
according to the USP. The SD powders also showed poor fl wability properties (CI 388 
values of about 31% and 28% for SD ABZ-SGC and SD ABZ-STC systems, 389 
respectively).  390 
The two main factors that generally affect powders flowability are particle shape and 391 
size. Spherical particles (> 50 µm) with smooth surfaces often flow better than rough 392 
non-spherical particles [41]. In addition, when particle size decreases, the flowability of 393 
the powder is reduced due to interparticle forces (primarily the Van der Waals attractive 394 
forces), which become larger in relation to gravitational and drag forces. Therefore, fine 395 
powders with median diameters smaller than 30 µm often exhibit poor flow and a 396 
tendency to agglomerate [42]. Since particles suitable for pulmonary delivery have to be 397 
very small, they are usually cohesive. Although the SD ABZ-STC and SD ABZ-SGC 398 
particles were more rounded than the raw material, the SD formulations presented 399 
particle sizes of 3.72 µm and 3.86 µm respectively (Table 2) and the poor flowability of 400 
the tested powders was expected. 401 
Dry powder inhalers are usually formulated as a powder mixture of coarse carrier 402 
particles [43] to improve drug particle flowability, thus improving dosing accuracy and 403 
minimizing the dose variability observed with drug formulations alone [28]. Hence, in 404 
this work the SD samples were mixed with lactose with excellent flow properties 405 
(CI=3.13, Table 3). 406 
 407 















The surface areas of SD ABZ-STC and SD ABZ-SGC samples were 10.8 m²/g and 8.8 409 
m²/g, respectively. These results could be attributed to both particle size and porosity. 410 
According to the pore volume distribution, the use of STC as surfactant resulted in 411 
enhanced product porosity. Figure 2 shows that bothSD particle systems have similar 412 
pore size distributions, SD ABZ-STC has pore diameters slighty larger than SD ABZ-413 
SGC. Moreover, SD ABZ-STC has more mesopores (2–50 nm) and macropores (> 50 414 
nm) than SD ABZ-SGC [44].  415 
It has been reported that when suspensions are dried by SD, agglomerate-like particles 416 
are formed. Typically, the transformation of the nanosuspensions into aggregates by 417 
spray drying employed pharmaceutical excipients, such as polymers, sugars and 418 
surfactants. They act by forming “excipient bridges”, interconnecting the nanoparticles 419 
[45]. The evaporation of water from sprayed droplets produces the agglomeration of 420 
particles, generating porous structures which enable further moisture evaporation through 421 
pores and capillaries [46]. These data agree with our analysis of surface area 422 
determination (Figure 2) and with the micrographs (Figure 1), where some pores are 423 
visible between the agglomerated crystals in both frmulations. Moreover, these results 424 
are in accordance with the low moisture levels in the obtained products (Table 2).    425 
The differences in porosity found in SD ABZ-STC and SD ABZ-SGC formulations 426 
could be attributed to the interaction between ABZ and the surfactants used. In this 427 
sense, based on the surface tension results (see Section 3.1), we concluded that SGC 428 
showed higher interaction with the suspended ABZ particles than STC. Therefore, SGC 429 
could generate more interparticle bridges, which would increase the nanoparticle 430 
proximity; and thus, it would decrease the porosity of the final microparticles. 431 
 432 
3.4.5. Aerosolization performance 433 
In order to analyze the quality of SD ABZ-STC and SD ABZ-SGC for pulmonary 434 
application, the aerosolization performance of the particle systems was evaluated by 435 















Several articles have demonstrated the effects of STC and SGC as enhancers of the 437 
absorption of hydrophobic drugs and peptides-proteins, both through the pulmonary 438 
route [17] and other routes of drug administration [18, 47-51]. However, to date, the 439 
capability of the bile salts as enhancers of the aerosolization properties has not been 440 
exhaustively explored. Li et al. [15] found that if STC was incorporated into non-viral 441 
gene therapy formulations prior to SD of the solutins, this resulted in a powder with 442 
cavities, with reduced deposition in the throat andstage 1 in the evaluation of in vitro 443 
deposition of dry powders. The results showed that STC improved the aerodynamic 444 
properties by deaggregation of the powder agglomerates [15]. 445 
Our results for different SD powder:lactose ratios showed that the EFs were above 90% 446 
for both SD powders (Table 4). On the other hand, the FPF and RF were significantly 447 
higher for SD ABZ-STC than for SD ABZ-SGC. According to these results, the 448 
performance of SD ABZ-STC was better than that of SD ABZ-SGC, which is consistent 449 
with the data previously reported. Porous particles ontain a high void space, producing 450 
particles with low density, leading to a low aerodynamic diameter, and consequently, 451 
high respiratory fractions [52]. As shown in Figure 2, the SD ABZ-STC presented higher 452 
porosity than SD ABZ-SGC, which may explain the differences in the percentages of 453 
respiratory fraction of each formulation.  454 
For a SD powder:lactose ratio of 1:2, the MMAD for SD ABZ-STC was about 1.9 µm, 455 
whereas the MMAD for SD ABZ-SGC was about 2.3 µm (Table 5). The differences 456 
between the MMAD values of both formulations were not statistically significant, but a 457 
tendency to lower MMAD for the SD ABZ-STC, compared to SD ABZ-SGC, was found. 458 
In order to administer a suitable drug dose by the pulmonary route, without significantly 459 
decreasing the flow properties, a SD powder-lactose ratio of 1:1 was used. The EF, FPF 460 
and RF values (Table 4) and the percentage of particles smaller than 5 µm and 3 µm 461 
(Table 5) for both formulations were similar to that obtained with a SD powder:lactose 462 















SD powder does not affect the aerodynamic behavior, and it would be a good approach 464 
for the administration of an effective dose of ABZ. 465 
For both SD powders and different powder:lactose ratios, the RF values were higher than 466 
70% (Table 4), and 90% of the particles presented an aerodynamic diameter below 5 µm 467 
(Table 5). The GSD values obtained (lower than 3) showed that the aerodynamic 468 
diameter distributions were narrow [53]. Therefore, th  formulations could be adequately 469 
deposited throughout all the regions of the lungs and effectively reach the lower airways 470 
[54].  471 
  472 
3.4.6. Aerodynamic behavior under special conditions 473 
Dyspnea is a frequent symptom in patients with pulmonary CE [4, 55]. In order to 474 
determine the performances of the SD ABZ-SGC and SD ABZ-STC powders under 475 
conditions that simulate reduced respiratory capacity, ascade impactor experiments 476 
were performed using a low pressure drop of 2 KPa (Section 2.5.6).  477 
As shown in Table 4, the RF of SD ABZ-STC:lactose (1:1) and SD ABZ-SGC:lactose 478 
(1:1) formulations were of 69.00% and 48.98%, respectiv ly (percentages lower than RF 479 
values obtained under normal respiratory conditions). I  addition, MMAD values and the 480 
percentage of particles smaller than 5 µm were similar to those obtained under normal 481 
conditions (Table 5). Even though the special conditions affected some aerodynamic 482 
parameters, all the values obtained are adequate for ABZ administration by inhalation.  483 
On the other hand, in agreement with our previous result under normal pressure drop 484 
(Section 3.4.5), the RF of SD ABZ-STC was significantly higher than SD ABZ-SGC. 485 
Again, it can be attributed to the higher porosity of SD ABZ-STC than SD ABZ-SGC 486 
[52]. 487 
 488 
3.4.7. Effects of ABZ dry powders on LS function 489 
LS plays an important role in ensuring lung functionality [56]. The analysis of the 490 















increase in this parameter is indicative of deteriorat n in the surface film and could lead 492 
to alveolar collapse. It has been proposed that, if the n vivo minimum surface tension 493 
exceeds 10 mN/m, this may lead to atelectasis [57].494 
In this work, the effects of the SD ABZ-STC and SD ABZ-SGC formulations on LS 495 
functionality were studied by constrained drop surfactometer (CDS). Sørli et al. analyzed 496 
the applicability of the CDS in vitro model as a predictor for lung toxicity in vivo both 497 
for impregnation products and for potential pharmaceuti al enhancers (bile salts, 498 
including the two used in the present study) [31, 58]. For impregnation products the in 499 
vitro - in vivo correlation demonstrated that all the analyzed proucts that induced acute 500 
respiration toxicity in mice upon inhalation also inhibited the LS function in vitro. 501 
Therefore, they concluded that this method may greatly reduce the number of animals 502 
used for toxicity testing and formulation of new products [58]. The bile salts induced 503 
rapid shallow breathing upon inhalation by mice, th concentration that induced rapid 504 
shallow breathing was ranked, and this rank was the ame as when compared to the 505 
concentration that inhibited LS function [31] . The bile salt concentrations tested in the 506 
paper by Sørli et al (2018) was much higher than in the present work. 507 
Figure 3 shows that when the SD ABZ-STC and SD ABZ-SGC powders were 508 
aerosolized and introduced into the CDS chamber, th minimum surface tension 509 
increased slightly compared to the baseline values, but they were all well below 10 510 
mN/m. Neither formulation affected the LS function at the analyzed doses, which 511 
suggests that the SD powders do not disrupt the LS function. 512 
 513 
4. Conclusions 514 
In the present work, two formulations containing the hydrophobic drug ABZ and the bile 515 
salts STC and SGC, for local delivery of ABZ through the pulmonary route, were 516 
developed and compared. Both products were obtained by processing aqueous 517 
suspensions using simple and scalable techniques, sch as high-pressure homogenization 518 















Our results demonstrate that although SGC is a better suspension stabilizer than STC, the 520 
formulation containing STC presented a better aerodynamic behavior, as a result of the 521 
higher porosity of the powder, compared with SD ABZ-SGC. Thus, we conclude that the 522 
bile salt type can differently affect the porosity of the nanoaggregates obtained, leading 523 
to formulations with different aerodynamic profiles, which is relevant for lung drug 524 
delivery applications. 525 
Nevertheless, both SD powders presented high yields, low moisture content and high 526 
percentages of respirable fraction (under normal and special conditions) and they did not 527 
affect the lung surfactant functionality. Thus, both formulations could be attractive 528 
strategies to target ABZ for the treatment of parasitic diseases affecting the respiratory 529 
system. However, drug dissolution and i  vivo studies should be performed to establish a 530 
correlation between the in vitro results obtained in this work and the efficacy of the531 
formulations. 532 
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Figure captions 764 
 765 
Figure 1. Morphology of ABZ raw material (A) and the SD powders of ABZ-STC (B) and 766 
ABZ-SGC (C) by scanning electron microscopy (SEM) at a magnification of 8500 X and 20000 767 
X. 768 
 769 
Figure 2. Barrett-Joyner-Halenda (BJH) pore size distribution from N2 adsorption isotherm 770 
expressed as pore volume. 771 
 772 
Figure 3. Minimum surface tension of the lung surfactant (LS) after administration of the spray 773 
drying products ABZ-SGC (A) and ABZ-STC (B) at doses between 1 and 11 ug/mg of LS. Data 774 















Table 1. Median volumetric diameter (D50) and distribution width (Span) of ABZ-STC and ABZ-SGC suspensions (initial suspensions 
and suspensions obtained after homogenization and sonication operations).  
 
 Raw material Suspension ABZ-STC  Suspension ABZ-SGC 













 (µm)  
 
76.31 ± 2.99 
 
44.97 ± 1.55 
 
21.65 ± 0.16 
 
11.87 ± 0.79 
  
14.90 ± 0.12 
(**) 
15.57 ± 0.25 
(**) 
6.08 ± 0.00 
(**) 
Span 11.4 1.95 2.52 2.28 
 
4.51 4.31 2.53 
Asterisks (*) indicate significant differences betwen D50 values of ABZ-STC and ABZ-SGC suspensions at each stage of the process. **, p < 0.01. 
 
 
Table 2. Particle size (D10, D50 and D90), outlet temperature, yield and moisture of SD ABZ-STC and SD ABZ-SGC powders.  
 
 
Yield (%) Oulet  
temperature (º C) Moisture (%) D10 (µm) D50 (µm) D90 (µm) Span 
ABZ-STC 50 ± 10 68 ± 1 0.70 ± 0.04 1.10 ± 0.09 3.72 ± 0.06 8.38 ± 0.40 1.96 
ABZ-SGC 60 ± 6 69 ± 1 0.56 ± 0.02 (*) 1.06 ± 0.02 3.86 ± 0.30 9.56 ± 0.80 2.20 
Asterisk (*) indicate significant differences between moisture values of ABZ-STC and ABZ-SGC SD powders. *, p < 0.05. 
 
 
Table 3. Bulk density, Tap density and Carr Index determinations of ABZ raw material, SD powders and 
lactose. 
 
Material  ABZ raw material  ABZ-STC ABZ-SGC Lactose 
δbulk (g/mL) 0.34 ± 0.01 0.28 ± 0.01 0.27 ± 0.00 0.66 ± 0.00 
δtap (g/mL) 0.53 ± 0.02 0.38 ± 0.01 0.40 ± 0.01 0.68 ± 0.01 
Carr Index  35.43 ± 1.54 27.61 ± 0.83 31.00 ± 1.41 3.13 ± 1.48 
















Table 4. Emitted fraction (EF), fine particle fraction (FPF) and respirable fraction (RF) of SD ABZ-
STC and SD ABZ-SGC powders under different operating conditions.  
 
  SD/Lactose 
ratio 
Pressure drop 
(Kpa) EF (%) FPF (%) RF (%) 
ABS-STC 
1:2 4 94.13 ± 1.46 83.40 ± 5.36 (*) 78.45 ± 3.83 
1:1 4 96.80 ± 2.40 79.90 ± 0.71 (*) 77.10 ± 1.06 (**) 
1:1 2 93.27 ± 2.41 73.95 ± 2.55 (**) (#) 69.00 ± 4.15 (**)(#) 
      
ABZ-SGC 
1:2 4 96.50 ± 0.51 74.20 ± 1.44 70.50 ±  3.45 
1:1 4  93.50 ± 1.08 76.50 ± 1.57 71.50 ± 2.29 
1:1 2 90.75 ± 0.78 53.97 ± 3.72  (###) 48.98 ± 2.94 (###) 
Asterisks (*) indicate significant differences of FP -RF values from SD ABZ-STC and ABZ-SGC, when comparing the 
same experimental conditions. Hashtags (#) indicate significant differences of FPF-RF values obtained when comparing the 
pressure drops of 4 kpa and 2 kpa, for each formulation. One symbol indicates p < 0.05; two symbols indicate p < 0.01 and 















Table 5. Aerodynamic diameter (D10, D50, D90 and D99), GSD and percentage of particles whose size are low r than 5 µm, 3 µm and 1 µm 















 (µm) Particles   
< 5 µm (%) 
Particles   
< 3 µm (%)  
Particles   
< 1 µm (%)  GSD 
ABS-STC 
1:2 4 0.65 ± 0.03 1.87 ± 0.20 4.05 ± 0.09 8.00 ± 0.84 91 ± 3 75 ± 4 23 ± 2 2.13 ± 0.04 
1:1 4 0.80 ± 0.01 2.21 ± 0.01 4.35 ± 0.06 8.02 ± 0.01 89 ± 1 67 ± 3 10 ± 1 1.99 ± 0.01 
1:1 2 0.76 ± 0.00 2.07 ± 0.01 4.07 ± 0.07 4.89 ± 0.15 92 ± 1 74 ± 1 10 ± 1 1.98 ± 0.01 
          
 
ABZ-SGC 
1:2 4 0.77 ± 0.06 2.25 ± 0.14 4.56 ± 0.33 7.92 ± 0.07 90 ± 1 64 ± 6 13 ± 1 2.05 ± 0.03 
1:1 4 0.77 ± 0.02 2.21 ± 0.05 4.46 ± 0.11 7.89 ± 0.01 89 ± 2 65 ± 3 10 ± 1 2.03 ± 0.00 
1:1 2 0.75 ± 0.04 2.20 ± 0.16 4.96 ± 0.51 6.59 ± 0.04 85 ± 4 65 ± 2 12 ± 1 2.15 ± 0.04 
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